Stockscreener 앱 받기
1.05
0.00%
0.00
전일 마감가:
$1.05
열려 있는:
$1.05
하루 거래량:
66,179
Relative Volume:
0.13
시가총액:
$24.83M
수익:
-
순이익/손실:
$-14.33M
주가수익비율:
-1.5909
EPS:
-0.66
순현금흐름:
$-13.21M
1주 성능:
-1.41%
1개월 성능:
+0.96%
6개월 성능:
+2.94%
1년 성능:
-22.22%
1일 변동 폭
$1.0286
$1.0686
1주일 범위
$1.0286
$1.16
52주 변동 폭
$0.8101
$2.10
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.05 | 25.51M | 0 | -14.33M | -13.21M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Will Enlivex Therapeutics Ltd. stock maintain dividend yieldMarket Activity Recap & Technical Analysis for Trade Confirmation - newser.com
Will Enlivex Therapeutics Ltd. stock gain from strong economyTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Why Enlivex Therapeutics Ltd. stock is considered a top pickWatch List & Real-Time Buy Signal Alerts - newser.com
Comparing Enlivex Therapeutics Ltd. in custom built stock radarsLayoff News & Smart Allocation Stock Reports - newser.com
Backtesting results for Enlivex Therapeutics Ltd. trading strategiesDollar Strength & AI Optimized Trade Strategies - newser.com
Can Enlivex Therapeutics Ltd. stock maintain operating margins2025 Top Decliners & Safe Capital Growth Tips - newser.com
Why analysts remain bullish on Enlivex Therapeutics Ltd. stockBull Run & Stock Timing and Entry Methods - newser.com
Trend analysis for Enlivex Therapeutics Ltd. this weekTrade Exit Summary & Community Consensus Trade Signals - newser.com
Has Enlivex Therapeutics Ltd. found a price floorTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
Technical signs of recovery in Enlivex Therapeutics Ltd.2025 Risk Factors & AI Enhanced Trade Execution Alerts - newser.com
Can Enlivex Therapeutics Ltd. stock deliver consistent earnings growthQuarterly Performance Summary & Technical Pattern Based Signals - newser.com
What’s the recovery path for long term holders of Enlivex Therapeutics Ltd.July 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Will Enlivex Therapeutics Ltd. stock deliver shareholder valueQuarterly Trade Report & High Accuracy Swing Trade Signals - newser.com
How Enlivex Therapeutics Ltd. stock reacts to job market dataDividend Hike & Low Risk Investment Opportunities - newser.com
How to recover losses in Enlivex Therapeutics Ltd. stock2025 Retail Activity & Weekly High Momentum Picks - newser.com
Published on: 2025-10-31 00:58:35 - newser.com
Published on: 2025-10-30 23:36:56 - newser.com
Using portfolio simulators with Enlivex Therapeutics Ltd. includedEarnings Recap Summary & AI Enhanced Execution Alerts - newser.com
Price action breakdown for Enlivex Therapeutics Ltd.Weekly Earnings Recap & Real-Time Stock Price Movement Reports - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Times Telegram
D. Boral Capital Maintains Enlivex Therapeutics (ENLV) Buy Recommendation - Nasdaq
ENLV Stock Rating Maintained at 'Buy' by D. Boral Capital | ENLV - GuruFocus
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Shelby Star
Risk Report: How Enlivex Therapeutics Ltd. stock responds to policy changesEarnings Recap Summary & Community Trade Idea Sharing Platform - fcp.pa.gov.br
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - The Manila Times
Enlivex Therapeutics Ltd. to Present Positive Phase IIa Clinical Data for Allocetra™ at ACR Convergence 2025 - Quiver Quantitative
Enlivex (Nasdaq: ENLV) to present 3-month data; pain and function improvement in knee OA - Stock Titan
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):